Deep learning model for assessing survival benefits in hepatocellular carcinoma patients undergoing intra-arterial therapies based on proliferative subtype

基于增殖亚型的深度学习模型用于评估接受动脉内治疗的肝细胞癌患者的生存获益

阅读:3

Abstract

The proliferative hepatocellular carcinoma (HCC) subtype is associated with aggressive disease and poor prognosis, yet it remains challenging to identify non-invasively. This retrospective multicenter study developed a multitask deep learning system for detecting proliferative HCC and predicting survival after intra-arterial therapy (IAT). Contrast-enhanced CT scans from two cohorts (surgical resection, n = 398; unresectable HCC receiving transarterial chemoembolization or hepatic arterial infusion chemotherapy, n = 1749) were analyzed using an nnUNet-based segmentation pipeline for liver and tumor delineation. A novel Prototype Mamba Net (PMN) architecture was created to extract imaging features indicative of proliferative biology. The model achieved AUCs of 0.825 (95% CI: 0.781-0.884) and 0.792 (95% CI: 0.732-0.841) on training and testing sets, respectively, for detecting proliferative HCC. Prognostic nomograms combining radiomic and clinical variables outperformed traditional staging systems (time-dependent AUC: 0.83-0.87; integrated Brier score: 0.12 versus 0.18-0.23, all P < 0.001). Among low-risk patients, no significant difference in survival was observed. However, for high-risk patients, HAIC showed a significant survival benefit compared to TACE (training and testing, P < 0.001). This non-invasive deep learning method enables preoperative identification of proliferative HCC and supports personalized IAT treatment choices, potentially improving outcomes in unresectable HCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。